Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD

Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis

Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment

Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment